Our major model systems include embryonic stem cells, neural stem cells, and cells of the hematopoietic system as well as sophisticated mouse models for tumors of the central nervous system and leukemia. We aim to understand the function of cancer-relevant chromatin-associated proteins, perform genetic screens to identify and characterize novel factors required for tumor maintenance, and collaborate with clinicians and biotech companies to translate our findings into the clinic. Ongoing projects include:

  • Molecular characterization of chromatin-associated proteins and their impact on histone modifications, DNA methylation, transcriptional regulation, and cell fate decisions
  • Development of new mouse models of cancer, including patient-derived xenografts and genetically engineered models of acute myeloid leukemia and brain cancers
  • Identification and molecular characterization of novel factors involved in the maintenance of embryonic and adult stem cells, acute myeloid leukemia, and tumors of the central nervous system
  • Development and characterization of small molecule inhibitors targeting several families of chromatin-associated enzymes